Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-2 and interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of interleukin-2 plus interferon alfa in treating adults with metastatic cancer.
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Biological: recombinant interferon alfa
|Study Design:||Primary Purpose: Treatment|
|Official Title:||OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER|
|Study Start Date:||August 1992|
|Study Completion Date:||February 1999|
|Primary Completion Date:||February 1998 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the response rate, failure-free survival, and overall survival of interleukin-2 and interferon alpha administered subcutaneously on an outpatient basis for 8 weeks to patients with metastatic cancer. II. Determine the toxicities associated with this therapy.
OUTLINE: Biological Response Modifier Therapy. Interleukin-2 (Cetus), IL-2, NSC-373364; Interferon alpha (Schering), IFN-A, NSC-377523.
PROJECTED ACCRUAL: Up to 30 patients with various malignancies will be entered.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002504
|United States, California|
|Hoag Memorial Hospital Presbyterian|
|Newport Beach, California, United States, 92658|
|United States, Indiana|
|Bloomington, Indiana, United States, 47402|
|St. Vincent Hospital and Health Care Center Research Department|
|Indianapolis, Indiana, United States, 46260|
|United States, Nebraska|
|Bergan Mercy Medical Center|
|Omaha, Nebraska, United States, 68124|
|United States, Tennessee|
|Baptist Regional Cancer Center - Knoxville|
|Knoxville, Tennessee, United States, 37901|
|Study Chair:||Robert O. Dillman, MD, FACP||Cancer Biotherapy Research Group|